Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.06 · Revenue $85.42M · 2 analysts
Est. EPS $0.01 · Revenue $98.55M · 2 analysts
Est. EPS $-0.77 · Revenue $316.56M · 4 analysts
Est. EPS $-0.01 · Revenue $96.65M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $175.1M | +216.9% | +27.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-221.2M | +33.8% | +42.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +87.1% | +1.8% | +0.3% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -91.4% | +81.8% | +79.9% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -126.3% | +79.1% | +54.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-166.8M | +37.5% | +87.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -95.2% | +80.3% | +90.1% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -48.3% | +39.3% | +1.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.73x | -58.7% | -13.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $259.1M | -31.5% | +7.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.03 vs -3.16 | +4.0% | -0.21 vs -0.06 | -229.7% |
| Revenue Surprise | $175.1M vs $174.5M | +0.3% | $74.3M vs $85.4M | -13.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 14, 2026 | Breedlove Robert Charles | officer: Principal Accounting Officer | Common Stock | D | 1,555 | $11.04 |
| May 22, 2026 | Parikh Asit | director | Common Stock | A | 28,000 | — |
| May 22, 2026 | Parikh Asit | director | Common Stock | D | 28,000 | — |
| May 20, 2026 | Parikh Asit | director | Common Stock | A | 17,500 | $4.95 |
| May 20, 2026 | Parikh Asit | director | Common Stock (Right to Buy) | D | 17,500 | $4.95 |
Operator: Good day, ladies and gentlemen. Hello, and welcome to Phathom Pharmaceuticals' Second Quarter 2026 Earnings Results Call. Please be advised that today's call is being recorded. With that, I would like to turn the call over to Eric Sciorilli, Phathom's Head of Investor Relations. Please go ahead, sir. Eric Sciorilli: Thank you, operator. Hello everyone, and thank you for joining us this morning to discuss Phathom's second quarter 2026 results. This morning's presentation will include remarks from Steve Basta, our President and CEO, and Sanjeev Narula, our Chief Financial and Business Officer. A couple of notes before we get started. Earlier this morning, we issued a press release detailing the results we will be discussing during the call. A copy of that press release can be found in the News Releases section of our corporate website. Further, the recording of today's webcast and the slides we will be reviewing can also be found on our corporate website under the Events and Presentations section. Before we begin, let me remind you that we will be making a number of forward-looking statements throughout today's presentation. These forward-looking statements involve risks and uncertainties, many of which are beyond Phathom's control. Actual results may materially differ from the forward-looking statements, and any such risks may materially adversely affect our business and results of operations and the trading prices for Phathom's common stock. A discussion of these statements and risk factors is available on the current Safe Harbor slide, as well as in the risk factors section of our most recent Form 10-K and subsequent SEC filings. All forward-looking statements made on this call are based on the beliefs of Phathom as of this date, and Phathom disclaims any obligation to update these statements. Later in the call, we will be commenting on both GAAP and non-GAAP financial measures. Specifically, in the scope of this discussion, when we refer to cash operating expenses, please note we are referring to the non-GAAP form of this measure, which excludes non-cash stock-based compensation. As always, detailed reconciliations between our non-GAAP results and the most directly comparable GAAP measures are included in this morning's press release. With that, I will now turn the call over to Steve Basta, Phathom's President and CEO, to kick us off. Steve? Steven Basta: Thank you, Eric, and thank you everyone for joining our call this morning. Let me start by highlighting the significant transition Phathom has made over the last year and a half. I'm very proud to share that for the first time in Phathom's history and ahead of our guidance, we generated positive operating profit in Q2, excluding stock-based compensation. That's a dramatic improvement compared to Q2 last year when our operating loss was more than $50 million. Importantly, from Q2 2025 to Q2 2026, we increased revenue by about 88% and reduced cash operating expenses by about 34%. We …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Azmi Nabulsi | Co-Founder | USD 1,950,012 | — | 1960 | Active |
David A. Socks | Co-Founder | USD 1,950,012 | Male | 1975 | Active |
Steven L. Basta | Chief Executive Officer, President & Director | USD 1,173,151 | Male | 1966 | Active |
Anne Marie Cook | Chief Legal Officer & Corporate Secretary | USD 663,406 | Female | 1962 | Active |
Sanjeev Narula | Chief Financial & Business Officer | USD 644,285 | Male | 1961 | Active |
Nancy R. Phelan | Senior Vice President of Marketing & Analytics | — | Female | 1969 | Active |
Bill Aprea | Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer | — | Male | — | Active |
Eric Sciorilli | Director of Business Development & Investor Relations | — | Male | — | Active |
Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training | — | Male | — | Active |
Paul Cocja | Chief People Officer | — | Male | — | Active |
Robert Breedlove | Vice President of Finance & Principal Accounting Officer | — | Male | — | Active |
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September:
Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the news Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the news
NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million–$325 million from its previously issued $320 million–$345 million range, falling below Wall Street consensus estimates of approximately $332 million. If you suffered a loss on your Phathom Pharmaceuticals investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via.
/PRNewswire/ -- Investors in Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) were told the Company's full-year revenue guidance was intact -- then watched that
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
